![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: HPSE2 |
Gene summary for HPSE2 |
![]() |
Gene information | Species | Human | Gene symbol | HPSE2 | Gene ID | 60495 |
Gene name | heparanase 2 (inactive) | |
Gene Alias | HPA2 | |
Cytomap | 10q24.2 | |
Gene Type | protein-coding | GO ID | GO:0006022 | UniProtAcc | Q8WWQ2 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
60495 | HPSE2 | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.31e-02 | 8.55e-02 | 0.0155 |
60495 | HPSE2 | HTA11_2487_2000001011 | Human | Colorectum | SER | 9.98e-05 | 2.00e-01 | -0.1808 |
60495 | HPSE2 | HTA11_347_2000001011 | Human | Colorectum | AD | 2.38e-07 | 1.81e-01 | -0.1954 |
60495 | HPSE2 | HTA11_1391_2000001011 | Human | Colorectum | AD | 1.09e-09 | 2.05e-01 | -0.059 |
60495 | HPSE2 | HTA11_10711_2000001011 | Human | Colorectum | AD | 6.53e-42 | 1.40e+00 | 0.0338 |
60495 | HPSE2 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 2.10e-02 | 1.70e-01 | 0.281 |
Page: 1 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05205 | Colorectum | AD | Proteoglycans in cancer | 70/2092 | 205/8465 | 1.37e-03 | 8.46e-03 | 5.39e-03 | 70 |
hsa052051 | Colorectum | AD | Proteoglycans in cancer | 70/2092 | 205/8465 | 1.37e-03 | 8.46e-03 | 5.39e-03 | 70 |
hsa052052 | Colorectum | SER | Proteoglycans in cancer | 58/1580 | 205/8465 | 4.37e-04 | 3.82e-03 | 2.77e-03 | 58 |
hsa052053 | Colorectum | SER | Proteoglycans in cancer | 58/1580 | 205/8465 | 4.37e-04 | 3.82e-03 | 2.77e-03 | 58 |
hsa052054 | Colorectum | MSS | Proteoglycans in cancer | 65/1875 | 205/8465 | 8.66e-04 | 5.38e-03 | 3.29e-03 | 65 |
hsa052055 | Colorectum | MSS | Proteoglycans in cancer | 65/1875 | 205/8465 | 8.66e-04 | 5.38e-03 | 3.29e-03 | 65 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
HPSE2 | insertion | Frame_Shift_Ins | rs778121647 | c.57_58insC | p.Ala20ArgfsTer45 | p.A20Rfs*45 | Q8WWQ2 | protein_coding | TCGA-AX-A05W-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
HPSE2 | insertion | Frame_Shift_Ins | rs778121647 | c.57dupC | p.Ala20ArgfsTer45 | p.A20Rfs*45 | Q8WWQ2 | protein_coding | TCGA-AX-A2HG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
HPSE2 | deletion | Frame_Shift_Del | c.57delN | p.Ala20ArgfsTer3 | p.A20Rfs*3 | Q8WWQ2 | protein_coding | TCGA-B5-A0K6-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |||
HPSE2 | SNV | Missense_Mutation | c.323N>A | p.Leu108His | p.L108H | Q8WWQ2 | protein_coding | deleterious(0) | possibly_damaging(0.62) | TCGA-LG-A6GG-01 | Liver | liver hepatocellular carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
HPSE2 | SNV | Missense_Mutation | c.136C>G | p.Pro46Ala | p.P46A | Q8WWQ2 | protein_coding | tolerated(0.68) | benign(0) | TCGA-50-5933-01 | Lung | lung adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | carboplatin | CR | |
HPSE2 | SNV | Missense_Mutation | novel | c.13N>A | p.Cys5Ser | p.C5S | Q8WWQ2 | protein_coding | deleterious_low_confidence(0) | benign(0) | TCGA-55-7910-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
HPSE2 | SNV | Missense_Mutation | c.511N>A | p.Asp171Asn | p.D171N | Q8WWQ2 | protein_coding | tolerated(0.07) | probably_damaging(0.996) | TCGA-55-7995-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | CR | |
HPSE2 | SNV | Missense_Mutation | novel | c.467N>C | p.Val156Ala | p.V156A | Q8WWQ2 | protein_coding | tolerated(0.17) | benign(0.015) | TCGA-55-8621-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
HPSE2 | SNV | Missense_Mutation | novel | c.218N>G | p.Thr73Arg | p.T73R | Q8WWQ2 | protein_coding | tolerated(0.55) | benign(0.276) | TCGA-75-6211-01 | Lung | lung adenocarcinoma | Female | Unknown | I/II | Unknown | Unknown | PD |
HPSE2 | SNV | Missense_Mutation | c.1667C>A | p.Pro556Gln | p.P556Q | Q8WWQ2 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-78-7166-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |